title: [Review of antidepressants from the TCAs to the third generation drugs].
abstract: Standpoints regarding the pathomechanism of unipolar major depressive disorder (MDD) and the relevant pharmaco-therapeutical possibilities are discussed in the paper. Generations of the antidepressants from the tri- and teracyclic drugs (TCAs) to the modern, dual-acting antidepressants, including the still popular selective serotonin reuptake inhibitors (SSRIs) are surveyed in more detailed. Pharmacodynamic properties of each antidepressant subgroup with the therapeutical benefits, the occasional side-effects and with some characteristic features of the detailed ingredients in certain cases are emphasized. Some benefits and possible disadvantages regarding the combinations are also discussed briefly. The main aim of this review is to give an objective approach to the psychiatrists in order to choose the best and optimal pharmaco-therapeutical method in their daily practice.
authors.affiliation: Organon Hungary Kft, Orvosi Osztály, Budapest.
authors.forename: János
authors.initials: J
authors.lastname: Almási
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Rihmer
mesh_terms: D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D018687:Antidepressive Agents, Second-Generation / Q000494:pharmacology / Q000627:therapeutic use; D000929:Antidepressive Agents, Tricyclic / Q000494:pharmacology / Q000627:therapeutic use; D016642:Bupropion / Q000494:pharmacology; D003511:Cyclohexanols / Q000494:pharmacology; D003521:Cyclopropanes / Q000494:pharmacology; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004338:Drug Combinations; D000068736:Duloxetine Hydrochloride; D006801:Humans; D008803:Mianserin / Q000031:analogs & derivatives* / Q000494:pharmacology; D000078764:Milnacipran; D000078785:Mirtazapine; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D009025:Morpholines / Q000494:pharmacology; D010879:Piperazines; D011743:Pyrimidines / Q000494:pharmacology; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D013876:Thiophenes / Q000494:pharmacology; D014196:Trazodone / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D000069470:Venlafaxine Hydrochloride
chemical_list: D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D016642:Bupropion; D003511:Cyclohexanols; D003521:Cyclopropanes; D004338:Drug Combinations; D000068736:Duloxetine Hydrochloride; D008803:Mianserin; D000078764:Milnacipran; D000078785:Mirtazapine; D008996:Monoamine Oxidase Inhibitors; D009025:Morpholines; D010879:Piperazines; D011743:Pyrimidines; D000077593:Reboxetine; D017367:Selective Serotonin Reuptake Inhibitors; D013876:Thiophenes; D014196:Trazodone; D014230:Triazoles; D000069470:Venlafaxine Hydrochloride; C051752:nefazodone; C039979:gepirone